Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.

摘要: BackgroundThe most prevalent phenotype of asthma is characterized by eosinophil-dominated inflammation that driven a type 2 helper T cell (Th2). Therapeutic targeting GATA3, an important transcription factor the Th2 pathway, may be beneficial. We evaluated safety and efficacy SB010, novel DNA enzyme (DNAzyme) able to cleave inactivate GATA3 messenger RNA (mRNA). MethodsWe conducted randomized, double-blind, placebo-controlled, multicenter clinical trial SB010 involving patients who had allergic with sputum eosinophilia also biphasic early late asthmatic responses after laboratory-based allergen provocation. A total 40 could evaluated; 21 were assigned receive 10 mg 19 placebo, each study drug administered means inhalation once daily for 28 days. An challenge was performed before 28-day period. The primary end point response as quanti...